Scientists track severe asthma in kids to uncover hidden patterns
NCT ID NCT02114034
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study follows 362 children with severe asthma to identify different types of the disease and what makes it worse. Researchers will track their health from childhood into adulthood to see how asthma changes over time. The goal is to find risk factors and improve treatment strategies for severe asthma.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict which children will have severe asthma and how it changes over time, leading to more personalized care.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. Results may take years and might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
362 people
The number who actually took part.
- Started
-
Nov 2013
- Expected to finish
-
Nov 2032
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Primary Care Clinic
- Ages
-
3 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Children with severe asthma: * Child aged 3 to 12 years * Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene or short acting nebulized bronchodilators (inhaler technique and compliance verified) presents one of the criteria following: * Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months * exacerbations in the previous year: * at least one care unit admission or continued resuscitation * at least two hospitalizations for acute severe asthma requiring IV therapy * at least 2 courses of oral corticosteroids for exacerbations * post BD FEV \<80% or UARS post BD\> 150% predicted * Signature of consent or the holder (s) of parental authority * Particular case of patients treated with Xolair® : Patients currently receiving Xolair® but who met the severity criteria of asthma, as described above, before the start of treatment with Xolair® are includable. Children with non-severe asthma: Inclusion Criteria * Child aged 3 to 12 years * Controlled without treatment or with low doses of inhaled corticosteroids (\<500 mg / day beclometasone equivalent) asthma * Child with normal EFR (Child over 4 years) * Child who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year * Child not admitted in the previous year for asthma. * Signature of consent or the holder (s) of parental authority Exclusion Criteria: * Child with bronchopulmonary dysplasia * Child with severe sequelae of viral infections * Refusal of the child or parents Data collection for research and follow up of patients : tests carried out in the 3 months prior to inclusion are used Blood sample for DNA extraction and the biobank: for young children, sampling at least 4 to 5 ml on dry tubes for serum and 6 ml at least for DNA. These samples should be stored at room temperature, transported within 48 hours to biological resources (CRB) Necker E,fa,ts Malades.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Severe asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Pneumologie et allergologie pédiatrique, Hôpital Necker-Enfants Malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single injection tame severe asthma in fungal allergy?
- Could a simple exercise programme boost asthma remission?
- A two-step strategy: biologic drug may pave the way for immunotherapy in severe olive pollen asthma
- Could a biologic drug free severe asthma patients from High-Dose steroids?
- Scientists probe why tezepelumab doesn't stop all asthma attacks
- Smart inhalers track Fasenra's asthma control over full dosing cycle